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Background: Hospital-acquired infections caused by multiresistant gram-negative bacteria are difficult to treat and
cause high rates of morbidity and mortality. The analysis of antimicrobial resistance trends of gram-negative
pathogens isolated from hospital-acquired infections is important for the development of antimicrobial stewardship
programs. The information obtained from antimicrobial resistant programs from two hospitals from Mexico will be
helpful in the selection of empiric therapy for hospital-acquired gram-negative infections.
Findings: Two thousand one hundred thirty two gram-negative bacteria collected between January 2005 and
December 2010 from hospital-acquired infections occurring in two teaching hospitals in Mexico were evaluated.
Escherichia coli was the most frequently isolated gram-negative bacteria, with >50% of strains resistant to
ciprofloxacin and levofloxacin. Klebsiella spp. showed resistance rates similar to Escherichia coli for ceftazidime (33.1%
vs 33.2%), but exhibited lower rates for levofloxacin (18.2% vs 56%). Of the samples collected for the third most
common gram-negative bacteria, Pseudomonas aeruginosa, >12.8% were resistant to the carbapenems, imipenem
and meropenem. The highest overall resistance was found in Acinetobacter spp. Enterobacter spp. showed high
susceptibility to carbapenems.
Conclusions: E. coli was the most common nosocomial gram-negative bacilli isolated in this study and was found
to have the second-highest resistance to fluoroquinolones (>57.9%, after Acinetobacter spp. 81.2%). This finding
represents a disturbing development in a common nosocomial and community pathogen.
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Rational for the surveillance of bacterial resistance trends
Gram-negative infections are responsible for a large por-
tion of device-associated infections, procedure-associated
infections, and healthcare-associated infections [1]. Recent
data from the National Healthcare Safety Network indi-
cate that gram-negative bacteria are responsible for more
than 30% of hospital-acquired infections and more than
40% of infections in patients in intensive care units [2,3].
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distribution, and reproduction in any mediumbacteria are difficult to manage, due to the increasingly
varied resistance mechanisms that these bacteria can de-
velop [4,5].The continuous surveillance of antibiotic re-
sistance trends in bacteria isolated from hospital-acquired
infections is essential for the selection of adequate initial
empiric therapy [6,7].The laboratory-based antibiograms
is efficacious as a guide for the rational selection of anti-
microbial therapy, and to alert healthcare providers to the
presence of unusual or emerging antimicrobial mechan-
isms [8]. The evaluation of antimicrobial resistance in
gram-negative bacterial strains in two Mexican hospitals
during 2005–2010 is presented.
Methods
The participating hospitals in this study are similar in
their patient characteristics. The Hospital Civil deentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Comparison of the in vitro activities of selected
antimicrobial agents tested against Escherichia coli (563
strains)
Antimicrobial agent MIC50 MIC90 Range % susceptible/
resistanta
Cefuroxime 8 >16 ≤2 – >16 55.2 / 43.2
Cefoxitin 4 >16 ≤4 – >16 74.9 / 13.7
Ceftriaxone ≤0.25 >32 ≤0.25 – >32 56.8 / 41.7
Ceftazidime ≤1 >16 ≤1 – >16 61.6 / 33.2
Cefepime 0.25 >16 ≤0.12 – >16 71.4 / 19.9
Piperacillin/tazobactam 4 32 ≤0.5 – >64 83.1 / 3.9
Imipenem ≤0.12 0.25 ≤0.12 – 1 100.0 / 0.0
Meropenem ≤0.12 ≤0.12 ≤0.12 – 0.5 100.0 / 0.0
Ciprofloxacin >4 >4 ≤0.03 – >4 41.7 / 57.9
Levofloxacin >4 >4 ≤0.5 – >4 41.7 / 56.7
Gentamicin ≤2 >8 ≤2 – >8 67.1 / 31.9
Amikacin ≤4 8 ≤4 – >32 95.7 / 0.4
PolymyxinBb ≤0.5 ≤0.5 ≤0.5 – 1 100 / 0.0
Colistinb ≤0.5 ≤0.5 ≤0.5 – 2 99.8 / 0.2
a Criteria as published by the CLSI [16].
b Pseudomonas aeruginosa breakpoints.
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care teaching hospital located in the city of Guadalajara,
the second largest city in Mexico. The Hospital General
de Durango is a 300-bed teaching hospital located in the
city of Durango, which is the capital of the state of Du-
rango in Mexico.
All isolates were identified at the participating insti-
tution by routine methodologies that are in use at
each laboratory. Upon receipt at the central monitor
(JMI Laboratories, North Liberty, IA, USA), isolates
were subcultured to ensure viability and purity. Con-
firmation of species identification was performed with
the Vitek system (bioMérieux Vitek, St Louis, MO)
[9,10].
A total of 2132 gram-negative bacteria were col-
lected between January 2005 and December 2010 and
were analyzed in the present study. The organisms
were consecutively collected according to the types of
infection, which primarily included bloodstream infec-
tions, skin and skin structure infections, and pneumo-
nia in hospitalized patients. The organisms evaluated
in this study included E. coli (563 strains), Klebsiella
spp. (329 strains), P. aeruginosa (404 strains), Acineto-
bacter spp. (362 strains) and Enterobacter spp. (214
strains).
Included among 260 other gram-negatives collected
were Citrobacter spp. (32 strains, including 26 Citrobac-
ter freundii), Proteus spp. (34 strains, including 29 Pro-
teus mirabilis), Serratia spp. (64 strains, including 61
Serratia marcescens), Stenotrophomonas maltophilia (37
strains), Pseudomonas fluorescens (10 strains), Salmon-
ella spp. (24 strains, including 2 Salmonella cholerasuis,
1 Salmonella paratyphi), and 59 (<3 isolates) other
gram-negatives.
Antimicrobial susceptibility testing was performed
using the broth microdilution method following the
recommendations of the Clinical and Laboratory Stan-
dards Institute, M07-A8 [11].Antimicrobial powders
were obtained from the respective manufacturers, and
microdilution plates were prepared by ThermoFisher
Scientific (formerly TREK Diagnostics; Cleveland, OH,
USA). The susceptibility results were interpreted accord-
ing to the Clinical Laboratory Standards Institute docu-
ment M100-S21 [12-16].
E. coli and Klebsiella pneumoniae isolates with MIC
values of ≥ 2 μg/mL for aztreonam and/or ceftazidime
and/or ceftriaxone were considered extended spectrum
betalactamases (ESBL) phenotypes[17,18]. Quality con-
trol was established by testing E. coli ATCC 25922, P.
aeruginosa ATCC 27853, Staphylococcus aureus ATCC
29213, and Streptococcus pneumoniae ATCC 49619.
Linear trend analysis for resistance trend over time
was performed using SPSS statistical software, version
17.0.Results
The most common gram-negative isolate was E. coli
(Table 1). Of the E. coli strains, 33.2% were resistant to
ceftazidime; >55% were resistant to the two fluoroqui-
nolones tested, ciprofloxacin and levofloxacin; and 31.9%
were resistant to gentamicin (Table 1). The E. coli iso-
lates were consistently susceptible to carbapenems and
amikacin, (100.0% and 95.7%, respectively), while pipera-
cillin/tazobactam was active against 83.1% of strains at
the susceptible breakpoint (Table 1).
Klebsiella spp. showed high resistant rates to ceftazi-
dime (33.1% compared to 24.0% in P. aeruginosa), but
relatively low resistance to fluoroquinolones (≤18.2% vs.
>50% in E. coli), more resistant to amikacin (13.1% vs.
0.4% in E. coli), and had similar susceptibility rates to
the carbapenems as E. coli, ≥ 98.4% (Table 2).
Of the isolated gram-negative bacteria, Pseudomonas
aeruginosa was the third most common organism after
E. coli and Klebsiella spp. (Table 3). P. aeruginosa exhib-
ited high resistance rates to the two carbapenems tested,
17.8% of the isolates were resistant to imipemen and
12.8% were resistant to meropenem (Table 3).
Acinetobacter spp, the fourth most common gram-
negative bacilli isolated during this study, was the most
resistant to the antimicrobials tested (Table 4). More
than 60% of the Acinetobacter spp. isolates were resistant
to all antibiotics tested, except imipenem (36.4% resist-
ance), meropenem (37.4% resistance) and colistin / poly-
myxin B, 1.5 / 1.4% resistance (Table 4).
Table 2 Comparison of the in vitro activities of selected
antimicrobial agents tested against Klebsiellaspp.a (329
strains)
Antimicrobial agent MIC50 MIC90 Range % susceptible/
resistantb
Cefuroxime 4 >16 ≤2 – >16 62.3 / 32.2
Cefoxitin ≤4 >16 ≤4 – >16 82.6 / 11.8
Ceftriaxone ≤0.25 32 ≤0.25 – >32 63.8 / 35.2
Ceftazidime ≤1 >16 ≤1 – >16 66.8 / 33.1
Cefepime ≤0.12 8 ≤0.12 – >16 92.7 / 4.5
Piperacillin/tazobactam 2 >64 ≤0.5 – >64 79.3 / 11.2
Imipenem 0.25 0.5 ≤0.12 – >8 98.4 / 1.2
Meropenem ≤0.12 0.25 ≤0.12 – >8 98.4 / 0.9
Ciprofloxacin ≤0.03 >4 ≤0.03 – >4 80.8 / 18.2
Levofloxacin ≤0.5 >4 ≤0.5 – >4 82.3 / 15.8
Gentamicin ≤2 >8 ≤2 – >8 82.6 / 14.5
Amikacin 2 >32 ≤4 – >32 84.1 / 13.1
PolymyxinB ≤0.5 ≤0.5 ≤0.5 – >4 99.2 / 0.6
Colistin ≤0.5 ≤0.5 ≤0.5 – >4 99.5 / 0.4
a Includes: Klebsiellaoxytoca (36 strains) Klebsiellapneumoniae (291 strains),
Klebsiellaornithinolytica (1 strain) and unspeciated Klebsiella (1 strain).
b Criteria as published by the CLSI [16].
c Pseudomonas aeruginosa breakpoints.
Table 4 Comparison of the in vitro activities of selected
antimicrobial agents tested against Acinetobacte spp.a
(362 strains)
Antimicrobial agent MIC50 MIC90 Range % susceptible /
resistantb
Ceftazidime >16 >32 ≤1 – >16 17.1 / 74.3
Cefepime 16 >16 ≤0.12 – >16 28.7 / 49.4
Piperacillin / tazobactam >64 >64 ≤0.5 – >64 16.3 / 77.9
Imipenem 4 >8 ≤0.12 – >8 52.3 / 36.4
Meropenem 4 >8 ≤0.12 – >8 52.3 / 37.4
Ciprofloxacin >4 >4 ≤0.03 – >4 18.2 / 81.2
Levofloxacin >4 >4 ≤0.5 – >4 18.7 / 78.1
Gentamicin >8 >8 ≤2 – >8 34.2 / 63.5
Amikacin >32 >32 ≤4 – >32 22.1 / 64.9
PolymyxinB ≤0.5 ≤0.5 ≤0.5 – >4 98.6 / 1.4
Colistin ≤0.5 1 ≤0.5 – >4 98.5 / 1.5
a Includes Acinetobacterbaumannii (295 strains), Acinetobacterhaemolyticus (3
strains), Acinetobacterlwoffii (16 strains), and unspeciated Acinetobacter (48
strains).
b Criteria as published by the CLSI [16].
Table 5 Comparison of the in vitro activities of selected
a
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gram-negative bacilli, had a different resistance pattern
than the other gram-negative bacilli tested (Table 5). All
(100.0%) Enterobacter spp. tested were susceptible to
imipenem and meropenem. Only 3.7% were resistant to
cefepime, 26.1% were resistant to piperacillin/tazobac-
tam, 14.0% were resistant to ciprofloxacin, and 12.6%
were resistant to levofloxacin (Table 5).Table 3 Comparison of the in vitro activities of selected
antimicrobial agents tested against Pseudomonas
aeruginosa (404 strains)
Antimicrobial agent MIC50 MIC90 Range % susceptible /
resistanta
Ceftazidime 2 >16 ≤1 – >16 71.7 / 24.0
Cefepime 4 16 0.5 – >16 77.9 / 9.9
Piperacillin/tazobactamb 8 >64 ≤0.5 – >64 68.8 / 15.5
Imipenem 2 >8 ≤0.12 – >8 74.9 / 17.8
Meropenem 0.5 >8 ≤0.12 – >8 76.4 / 12.8
Ciprofloxacin 0.25 >4 ≤0.03 – >4 75.2 / 20.0
Levofloxacin ≤0.5 >4 ≤0.5 – >4 74.2 / 24.0
Gentamicin ≤2 >8 ≤2 – >8 64.1 / 31.9
Amikacin 4 >32 ≤4 – >32 70.3 / 23.7
PolymyxinB 1 1 ≤0.5 – 2 100.0 / 0.0
Colistin 1 2 ≤0.5 – 2 100.0 / 0.0
a Criteria as published by the CLSI [16].
b Criteria published by the CLSI [15].During the observation period E. coli with an ESBL
phenotype increased from 35.0% in 2005 to 52.4% in
2010(p< 0.008), Klebsiella spp. with an ESBL phenotype
increased from 40.5% in 2005 to 43.8% in 2010,
imipenem-non-susceptible Klebsiella spp.phenotype
decreased from 8.1% in 2005 to 2.1% in 2010,
ceftazidime-resistant Enterobacter spp.phenotype
increased from 32.7% in 2005 to 46.4% in 2010,
imipenem-non-susceptible Enterobacter spp. phenotypeantimicrobial agents tested against Enterobacterspp.
(214 strains)
Antimicrobial agent MIC50 MIC90 Range %susceptible /
resistantb
Ceftriaxone 0.25 >32 ≤0.25 – >32 59.3 / 39.2
Ceftazidime ≤1 >16 ≤1 – >16 62.6 / 34.5
Cefepime ≤0.12 8 ≤0.12 – >16 92.1 / 3.7
Piperacillin / tazobactam 2 >64 ≤0.5 – >64 73.8 / 26.1
Imipenem 0.5 1 ≤0.12 – 8 98.6 / 0.0
Meropenem ≤0.12 0.12 ≤0.12 – 4 100.0 / 0.0
Ciprofloxacin ≤0.03 >4 ≤0.03 – >4 85.0 / 14.0
Levofloxacin ≤0.5 >4 ≤0.5 – >4 87.4 / 12.6
Gentamicin ≤2 >8 ≤2 – >8 81.3 / 18.6
Amikacin 2 >32 ≤4 – >32 82.7 / 16.3
PolymyxinB ≤0.5 >4 ≤0.5 – >4 - / -
Colistin ≤0.5 >4 ≤0.5 – >4 - / -
a Includes Enterobacteraerogenes (38 strains), Enterobacteramnigenus (2 strains),
Enterobactercancerogenus (1 strain), Enterobacter cloacae (161 strains),
Enterobactergergoviae (6 strains), Enterobactersakazakii (4 strains), and
unspeciated Enterobacter (2 strains).
b Criteria as published by the CLSI [16].
Table 6 Yearly variation of main resistance phenotypes
Resistance phenotype Year of isolation (Total/Percentage)
2005 2006 2007 2008 2009 2010
E. coli ESBL phenotypea,f 36 (35.0) 26(37.7) 29(38.7) 42(40.0) 45(54.2) 67(52.4)
Klebsiella spp. ESBL phenotypea 37(40.5) 17(33.3) 27(41.5) 7.8(20.0) 15(36.6) 21(43.8)
Imipenem-NSKlebsiellab 7(8.1) 2(2.0) 3(4.6) 0.00 2(4.9) 1(2.1)
Ceztazidime-R Enterobacterc 16(32.7) 6(16.7) 14(34.1) 10(37.0) 17(47.2) 13(46.4)
Imipenem-NS – Enterobacterd 1(2.0) 0.00 2(4.5) 4(14.8) 2(5.6) 1(3.6)
Imipenem-R Acinetobactere,f 4(13.8) 3(8.8) 6(20.0) 40(48.9) 33(65.6) 54(63.5)
Imipenem-R P. aeruginosae 13(16.8) 26(32.1) 13(27.1) 21(27.3) 13(25.0) 16(22.1)
a Defined as MIC ≥2 μg/ml for ceftazidime or ceftriaxone or aztreonam [CLSI, 2011].
b Imipenem MIC of ≥2 μg/ml [CLSI, 2011].
c Ceftazidime MIC of ≥16 μg/ml [CLSI, 2011].
d Imipenem MIC of ≥2 μg/ml [CLSI, 2011].
e Imipenem MIC of ≥8 μg/ml [CLSI, 2011].
f Resistance trend over time p<0.05.
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resistant Acinetobacter spp. phenotype increased from
13.8% in 2005 to 63.5% in 2010 (p< 0.001), and the
imipenem-resistant P. aeruginosa phenotype increased
from 16.8% in 2005 to 22.1% in 2010 (Table 6).
Summary and implications
Overall the resistance pattern found in our analysis in K.
pneumoniae, P. aeruginosa, Acinetobacter spp., and
Enterobacter spp. is similar to that described in other
Mexican and Latin American studies[19-24].
The similar susceptibility to ceftazidime and ceftriax-
one in E.coli and Klebsiella spp. suggests that CTX-M-
beta-lactamases are present in our hospitals although not
as widely disseminated as it occurred in the United States
of America where susceptibility to ceftriaxone is much
lower when compared to ceftazidime [25]. The produc-
tion of CTX-M-type beta-lactamases in association with
the production of other extended-spectrum-beta-lacta-
mases have been reported in other areas in Mexico
[19,20]. Certain resistant phenotypes encountered in this
study are to be examined carefully, including the ESBL
phenotype increase in E. coli, and the imipenem resistant
phenotype increase in Acinetobacter spp.
The emergence of resistance to carbapenems and the
lack of options for the treatment of P. aeruginosa infec-
tions with the exception of colistin and polymyxin B are
considerable [25,26].
Some of the limitations of our report include the lack
of resistance genotyping and of molecular strain typing.
The surveillance data presented by this study will help
to guide clinicians in our hospitals in the selection of ap-
propriate empiric antimicrobial treatment when con-
fronted with gram-negative infections. Our findings can
be used to monitor the evolution of bacterial resistance
in other similar hospitals and will be helpful for the de-
velopment of antibiotic stewardship programs.Competing interests
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